Navigation Links
Cempra Pharmaceuticals to Present at Two Upcoming Cambridge Healthtech Institute (CHI) Conferences
Date:4/7/2011

CHAPEL HILL, N.C., April 7, 2011 /PRNewswire/ -- Cempra Pharmaceuticals Inc. today announced that Prabhavathi Fernandes, Ph.D., president and chief executive officer, will present at two upcoming CHI conferences.  Dr. Fernandes will present at the Second Annual Anti-Inflammatories: Small Molecule Approaches Conference at 5 p.m. PDT, April 12, at the Hilton San Diego Resort in San Diego.  Her presentation is entitled "Macrolides as a New Class of Orally Active Anti-Inflammatory Agents." Her presentation will include a discussion on the mechanism of macrolide action as anti-inflammatory agents and the use of macrolides in COPD patients. Data on the potent anti-inflammatory activities of solithromycin (CEM-101), Cempra's fluoroketolide candidate in Phase 2 clinical development for community-acquired bacterial pneumonia (CABP), as well as novel macrolides without antibacterial activity will be presented.

Dr. Fernandes will present at the Fifth Annual Resistance is Futile: The Challenge of Antibacterial Drug Development Conference at 10:45 a.m. PDT, April 13, at the Hilton San Diego Resort in San Diego.  Her presentation is entitled "Solithromycin: A Well-Tolerated Fluoroketolide with Broad Spectrum, Potent Activity" and will provide an overview of the potential clinical value of an oral and intravenous macrolide in treating drug-resistant pathogens.

About Cempra Pharmaceuticals

Founded in 2006, Cempra Pharmaceuticals is a privately-held, clinical-stage biotechnology company focused on developing antibacterials to address critical medical needs. Two lead products, both in late-stage clinical trials, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra is well-funded and is committed to developing commercially viable products through consideration of pricing and reimbursement issues throughout its products' lifecycles. The company is also utilizing its proprietary chemistry technology to develop macrolides without antibacterial activity for non-antibiotic uses in motilin receptor activity, anti-inflammatory activity and GnRH receptor antagonism. Additional information about Cempra can be found at www.cempra.com.

Media Contacts:
Robert E. Flamm, Ph.D.
Russo Partners, LLC
(212) 845-4226
Robert.flamm@russopartnersllc.com

Tony Russo, Ph.D.
Russo Partners, LLC
(212) 845-4251
Tony.russo@russopartnersllc.com


'/>"/>
SOURCE Cempra Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cempra Pharmaceuticals to Present at Two Upcoming Investor Conferences
2. Cempra Expands Clinical Management Team to Advance Leading Antibacterial Clinical Programs Solithromycin and TAKSTA™
3. Cempra Pharmaceuticals Names Carl Foster Executive Vice President of Business Development
4. Cempra Pharmaceuticals Names Richard Kent, M.D., to Its Board of Directors
5. Cempra Pharmaceuticals to Present at the UBS Global Life Sciences Conference
6. Cempra Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
7. Cempra Pharmaceuticals To Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17th
8. Presentations of Cempra Pharmaceuticals CEM-102 (fusidic acid) at the Infectious Diseases Society of America Annual Meeting Highlight Properties That Make It an Excellent Anti-MRSA Candidate
9. Data Presented on Cempra Pharmaceuticals CEM-101 at the Infectious Diseases Society of America Annual Meeting Reinforces Potency and Coverage Against Multidrug-Resistant S. Pneumoniae Isolates
10. Reportlinker Adds Global: Pharmaceuticals Industry Guide
11. Optimer Pharmaceuticals and Cubist Pharmaceuticals Announce Collaboration to Co-Promote DIFICID™ (Fidaxomicin) for Clostridium difficile Infection in the United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Fla. , Jan. 19, 2017  Sensus ... medical device company specializing in the treatment of ... as keloids, with superficial radiation therapy, today announced ... full year 2016 financial results on Thursday, February 2, ... Company will hold a conference call with the ...
(Date:1/19/2017)... , January 19, 2017 ... announced that the U.S. Food and Drug Administration (FDA) ... a New Drug Application (NDA) for SHP465, a long-acting, ... as a potential once-daily treatment for Attention-Deficit/Hyperactivity Disorder (ADHD). ... or around June 20, 2017, the designated Prescription Drug ...
(Date:1/19/2017)... January 19, 2017 Pfizer ... the Milner Therapeutics Consortium   Major ... Cambridge   The Milner ... PFE ) as a partner to the Milner Therapeutics ... enables the efficient transfer of materials between industry and ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... January 20, 2017 , ... A new partnership between Goodwill® ... no longer use or need, from clothes to couches to dressers and bicycles. Roadie ... take them to the nearest Goodwill donation center through February 28th. , “January ...
(Date:1/20/2017)... Florida (PRWEB) , ... January 20, 2017 , ... Lice ... head lice cases in families with school-aged children since the holiday season. , ... the holidays with their families, sharing hugs and taking photos, which is the head-to-head ...
(Date:1/20/2017)... ... January 20, 2017 , ... Vitamin Well ... VW+ 002. The drinks have been produced in collaboration with Zlatan Ibrahimovic and ... your workout. , After a successful launch in Sweden last year, the next ...
(Date:1/20/2017)... ... 2017 , ... D R Burton Healthcare Products LLC, makers ... in a study indicating superior performance against competitive products in secretion clearance. ... Positive Expiratory Pressure Devices During Simulated Breathing“ was published in the winter issue ...
(Date:1/20/2017)... ... ... Miracle Man: Against All Odds”: an inspiring affirmation of God’s work. “God's Miracle ... son of Minister Delores Pinnock and a Jamaican native who lives in Kingston and ... up in bed, I felt a pounding headache. It was like a drum beating ...
Breaking Medicine News(10 mins):